Literature DB >> 27578326

The Use of Cytochrome C Oxidase Enzyme Activity and Immunohistochemistry in Defining Mitochondrial Injury in Kidney Disease.

Zsuzsanna K Zsengellér1,2, Seymour Rosen3,4,2.   

Abstract

The renal biopsy is a dynamic way of looking at renal disease, and tubular elements are an important part of this analysis. The mitochondria in 20 renal biopsies were examined by immunohistochemical (electron transport chain enzyme: cytochrome C oxidase IV [COX IV]) and enzyme histochemical methods (COX), both by light and electron microscopy. The distal convoluted tubules and thick ascending limbs showed the greatest intensity in the COX immunostains and enzyme activity in controls. The degree of mitochondrial COX protein and enzyme activity diminished as the tubules became atrophic. With proximal hypertrophic changes, there was great variation in both COX activity and protein expression. In contrast, in three cases of systemic lupus erythematosus, biopsied for high-grade proteinuria, the activity was consistently upregulated, whereas protein expression remained normal. These unexpected findings of heterogeneous upregulation in hypertrophy and the dyssynchrony of protein expression and activity may indicate mitochondrial dysregulation. Functional electron microscopy showed COX activity delineated by the intense mitochondrial staining in normal or hypertrophic proximal tubules. With atrophic changes, residual small mitochondria with diminished activity could be seen. With mitochondrial size abnormalities (enlargement and irregularity, adefovir toxicity), activity persisted. In the renal biopsy, mitochondrial analysis is feasible utilizing immunohistochemical and enzyme histochemical techniques.
© 2016 The Histochemical Society.

Entities:  

Keywords:  adefovir nephrotoxicity; atrophy; chronic allograft nephropathy (CAN); chronic kidney disease (CKD); cytochrome C oxidase; end-stage renal disease (ESRD); enzyme histochemistry; functional electron microscopy; hypertension; hypertrophy; lupus erythematosus; megamitochondria; transplantation

Mesh:

Substances:

Year:  2016        PMID: 27578326      PMCID: PMC5006138          DOI: 10.1369/0022155416660291

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  33 in total

Review 1.  Cytochrome oxidase in health and disease.

Authors:  Antoni Barrientos; Mario H Barros; Isabelle Valnot; Agnes Rötig; Pierre Rustin; Alexander Tzagoloff
Journal:  Gene       Date:  2002-03-06       Impact factor: 3.688

2.  A BIOCHEMICAL APPROACH TO THE STUDY OF REJECTION OF CANINE RENAL HOMOTRANSPLANTS. 3. HISTOCHEMICAL STUDIES OF TRANSPLANTED KIDNEYS.

Authors:  D T JANIGAN; M A WILLIAMS; H M TYLER; W J DEMPSTER
Journal:  Br J Exp Pathol       Date:  1964-08

3.  Proximal Tubules Have the Capacity to Regulate Uptake of Albumin.

Authors:  Mark C Wagner; Silvia B Campos-Bilderback; Mahboob Chowdhury; Brittany Flores; Xianyin Lai; Jered Myslinski; Sweekar Pandit; Ruben M Sandoval; Sarah E Wean; Yuan Wei; Lisa M Satlin; Roger C Wiggins; Frank A Witzmann; Bruce A Molitoris
Journal:  J Am Soc Nephrol       Date:  2015-06-08       Impact factor: 10.121

Review 4.  Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase.

Authors:  B Kadenbach; M Hüttemann; S Arnold; I Lee; E Bender
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

5.  Tenofovir renal toxicity targets mitochondria of renal proximal tubules.

Authors:  James J Kohler; Seyed H Hosseini; Amy Hoying-Brandt; Elgin Green; David M Johnson; Rodney Russ; Dung Tran; C Michael Raper; Robert Santoianni; William Lewis
Journal:  Lab Invest       Date:  2009-03-09       Impact factor: 5.662

6.  Disconnecting mitochondrial content from respiratory chain capacity in PGC-1-deficient skeletal muscle.

Authors:  Glenn C Rowe; Ian S Patten; Zsuzsanna K Zsengeller; Riyad El-Khoury; Mitsuharu Okutsu; Sophia Bampoh; Nicole Koulisis; Caitlin Farrell; Michael F Hirshman; Zhen Yan; Laurie J Goodyear; Pierre Rustin; Zolt Arany
Journal:  Cell Rep       Date:  2013-05-23       Impact factor: 9.423

7.  Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.

Authors:  Grace A McComsey; Eric S Daar; MaryAnn O'Riordan; Ann C Collier; Lisa Kosmiski; Jorge L Santana; Carl J Fichtenbaum; Heidi Fink; Paul E Sax; Daniel E Libutti; Mariana Gerschenson
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

8.  Severe renal mass reduction impairs recovery and promotes fibrosis after AKI.

Authors:  Aaron J Polichnowski; Rongpei Lan; Hui Geng; Karen A Griffin; Manjeri A Venkatachalam; Anil K Bidani
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

Review 9.  Cytochrome c oxidase.

Authors:  C Ostermeier; S Iwata; H Michel
Journal:  Curr Opin Struct Biol       Date:  1996-08       Impact factor: 6.809

Review 10.  Transforming growth factor-β and the progression of renal disease.

Authors:  Ivonne Loeffler; Gunter Wolf
Journal:  Nephrol Dial Transplant       Date:  2013-09-12       Impact factor: 5.992

View more
  3 in total

1.  The Multicomponent, Multitarget Therapy SUC in Cats with Chronic Kidney Disease: A Multicenter, Prospective, Observational, Nonrandomized Cohort Study.

Authors:  Uta Brandenburg; Gabriele Braun; Peter Klein; Erich Reinhart
Journal:  Complement Med Res       Date:  2020-03-26       Impact factor: 1.211

2.  Effects of transcription factor EB on oxidative stress and apoptosis induced by high glucose in podocytes.

Authors:  Yingli Kang; Ying Li; Tao Zhang; Yanqing Chi; Maodong Liu
Journal:  Int J Mol Med       Date:  2019-05-24       Impact factor: 4.101

3.  Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD.

Authors:  Zsuzsanna K Zsengellér; Agnes Lo; Mahtab Tavasoli; Elizabeth Pernicone; S Ananth Karumanchi; Seymour Rosen
Journal:  Kidney Int Rep       Date:  2019-08-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.